Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery
Completed
- Conditions
- Recovery Time
- Registration Number
- NCT06745492
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This study is a prospective observational study. A total of 54 patients were included in this study. We observed the time from neostigmine administration to TOF ratio of 1.0.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 59
Inclusion Criteria
- Patients undergoing elective thyroid surgery under general anesthesia
- a body mass index of 18.5-25 kg/m2
- Age ≥ 20
Exclusion Criteria
- Refused to participate
- history of hypersensitivity to acetylcholinesterase inhibitor
- neuromuscular disease
- hepatic or renal dysfunction
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recovery time During surgery Time from neostigmine administration to TOF ratio of 1.0
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie neostigmine's acceleration of neuromuscular recovery at TOF 0.7?
How does low-dose neostigmine compare to standard reversal agents like sugammadex in accelerating TOF recovery?
Are specific biomarkers associated with faster TOF ratio recovery following low-dose neostigmine administration?
What adverse event profiles distinguish low-dose neostigmine from standard-dose regimens in neuromuscular blockade reversal?
What combination therapies enhance neuromuscular recovery when paired with low-dose neostigmine at TOF 0.7?
Trial Locations
- Locations (1)
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of